nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—stomach cancer	0.225	1	CbGaD
Naloxone—ABCB1—Mitomycin—stomach cancer	0.0913	0.241	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—stomach cancer	0.0459	0.121	CbGbCtD
Naloxone—ALB—Irinotecan—stomach cancer	0.0448	0.118	CbGbCtD
Naloxone—ALB—Fluorouracil—stomach cancer	0.043	0.113	CbGbCtD
Naloxone—CYP2C8—Fluorouracil—stomach cancer	0.0332	0.0875	CbGbCtD
Naloxone—ALB—Methotrexate—stomach cancer	0.0237	0.0624	CbGbCtD
Naloxone—ABCB1—Irinotecan—stomach cancer	0.0234	0.0617	CbGbCtD
Naloxone—ABCB1—Docetaxel—stomach cancer	0.0172	0.0452	CbGbCtD
Naloxone—CYP3A4—Irinotecan—stomach cancer	0.014	0.037	CbGbCtD
Naloxone—ABCB1—Doxorubicin—stomach cancer	0.0128	0.0337	CbGbCtD
Naloxone—ABCB1—Methotrexate—stomach cancer	0.0124	0.0327	CbGbCtD
Naloxone—CYP3A4—Docetaxel—stomach cancer	0.0103	0.0271	CbGbCtD
Naloxone—CYP3A4—Doxorubicin—stomach cancer	0.00767	0.0202	CbGbCtD
Naloxone—Piloerection—Irinotecan—stomach cancer	0.00643	0.071	CcSEcCtD
Naloxone—TLR4—bone marrow—stomach cancer	0.00474	0.0743	CbGeAlD
Naloxone—TLR4—liver—stomach cancer	0.00383	0.0601	CbGeAlD
Naloxone—CREB1—hematopoietic system—stomach cancer	0.00325	0.051	CbGeAlD
Naloxone—CREB1—epithelium—stomach cancer	0.00298	0.0467	CbGeAlD
Naloxone—TLR4—lymph node—stomach cancer	0.00294	0.0461	CbGeAlD
Naloxone—CREB1—smooth muscle tissue—stomach cancer	0.00287	0.045	CbGeAlD
Naloxone—ALB—gall bladder—stomach cancer	0.00265	0.0416	CbGeAlD
Naloxone—CREB1—pancreas—stomach cancer	0.00265	0.0416	CbGeAlD
Naloxone—Injection site reaction—Mitomycin—stomach cancer	0.00255	0.0282	CcSEcCtD
Naloxone—ESR1—blood vessel—stomach cancer	0.00241	0.0377	CbGeAlD
Naloxone—CREB1—lymphoid tissue—stomach cancer	0.00229	0.0359	CbGeAlD
Naloxone—Pulmonary oedema—Mitomycin—stomach cancer	0.00228	0.0252	CcSEcCtD
Naloxone—CREB1—digestive system—stomach cancer	0.00226	0.0355	CbGeAlD
Naloxone—CREB1—bone marrow—stomach cancer	0.00209	0.0327	CbGeAlD
Naloxone—Shivering—Capecitabine—stomach cancer	0.002	0.0221	CcSEcCtD
Naloxone—CREB1—endocrine gland—stomach cancer	0.00187	0.0293	CbGeAlD
Naloxone—OPRM1—hematopoietic system—stomach cancer	0.00175	0.0275	CbGeAlD
Naloxone—CREB1—liver—stomach cancer	0.00169	0.0264	CbGeAlD
Naloxone—Encephalopathy—Fluorouracil—stomach cancer	0.00166	0.0184	CcSEcCtD
Naloxone—Abdominal cramps—Irinotecan—stomach cancer	0.00165	0.0182	CcSEcCtD
Naloxone—SLCO1A2—hematopoietic system—stomach cancer	0.00151	0.0237	CbGeAlD
Naloxone—Sneezing—Capecitabine—stomach cancer	0.00135	0.0149	CcSEcCtD
Naloxone—CREB1—lymph node—stomach cancer	0.00129	0.0203	CbGeAlD
Naloxone—ESR1—hematopoietic system—stomach cancer	0.00128	0.0201	CbGeAlD
Naloxone—ESR1—epithelium—stomach cancer	0.00117	0.0184	CbGeAlD
Naloxone—Encephalopathy—Capecitabine—stomach cancer	0.00116	0.0128	CcSEcCtD
Naloxone—Nervous system disorder—Floxuridine—stomach cancer	0.00114	0.0126	CcSEcCtD
Naloxone—ESR1—smooth muscle tissue—stomach cancer	0.00113	0.0177	CbGeAlD
Naloxone—CYP2C8—hematopoietic system—stomach cancer	0.00106	0.0166	CbGeAlD
Naloxone—SLCO1A2—digestive system—stomach cancer	0.00105	0.0165	CbGeAlD
Naloxone—OPRM1—endocrine gland—stomach cancer	0.00101	0.0158	CbGeAlD
Naloxone—Coma—Fluorouracil—stomach cancer	0.000975	0.0108	CcSEcCtD
Naloxone—Ventricular fibrillation—Capecitabine—stomach cancer	0.000974	0.0108	CcSEcCtD
Naloxone—Hypertension—Mitomycin—stomach cancer	0.000969	0.0107	CcSEcCtD
Naloxone—Rhinorrhoea—Docetaxel—stomach cancer	0.000951	0.0105	CcSEcCtD
Naloxone—ABCB1—blood vessel—stomach cancer	0.00095	0.0149	CbGeAlD
Naloxone—Body temperature increased—Floxuridine—stomach cancer	0.000922	0.0102	CcSEcCtD
Naloxone—Abdominal pain—Floxuridine—stomach cancer	0.000922	0.0102	CcSEcCtD
Naloxone—Rhinorrhoea—Capecitabine—stomach cancer	0.000921	0.0102	CcSEcCtD
Naloxone—ESR1—lymphoid tissue—stomach cancer	0.000902	0.0141	CbGeAlD
Naloxone—ESR1—digestive system—stomach cancer	0.000891	0.014	CbGeAlD
Naloxone—SLCO1A2—endocrine gland—stomach cancer	0.000868	0.0136	CbGeAlD
Naloxone—Encephalopathy—Methotrexate—stomach cancer	0.000865	0.00956	CcSEcCtD
Naloxone—Asthenia—Floxuridine—stomach cancer	0.000837	0.00925	CcSEcCtD
Naloxone—Dyspnoea—Mitomycin—stomach cancer	0.000816	0.00902	CcSEcCtD
Naloxone—Diarrhoea—Floxuridine—stomach cancer	0.000798	0.00882	CcSEcCtD
Naloxone—Pain—Mitomycin—stomach cancer	0.000783	0.00865	CcSEcCtD
Naloxone—SLCO1A2—liver—stomach cancer	0.000783	0.0123	CbGeAlD
Naloxone—ALB—liver—stomach cancer	0.000778	0.0122	CbGeAlD
Naloxone—Cardiac arrest—Irinotecan—stomach cancer	0.000769	0.0085	CcSEcCtD
Naloxone—Injection site reaction—Docetaxel—stomach cancer	0.000766	0.00846	CcSEcCtD
Naloxone—Vomiting—Floxuridine—stomach cancer	0.000742	0.0082	CcSEcCtD
Naloxone—Injection site reaction—Capecitabine—stomach cancer	0.000742	0.00819	CcSEcCtD
Naloxone—Irritability—Fluorouracil—stomach cancer	0.00074	0.00817	CcSEcCtD
Naloxone—Cardiac arrest—Fluorouracil—stomach cancer	0.000737	0.00814	CcSEcCtD
Naloxone—ESR1—endocrine gland—stomach cancer	0.000736	0.0115	CbGeAlD
Naloxone—Body temperature increased—Mitomycin—stomach cancer	0.000724	0.008	CcSEcCtD
Naloxone—CYP3A4—hematopoietic system—stomach cancer	0.000715	0.0112	CbGeAlD
Naloxone—Nausea—Floxuridine—stomach cancer	0.000693	0.00766	CcSEcCtD
Naloxone—Nasopharyngitis—Fluorouracil—stomach cancer	0.000693	0.00765	CcSEcCtD
Naloxone—Pulmonary oedema—Docetaxel—stomach cancer	0.000686	0.00758	CcSEcCtD
Naloxone—ESR1—liver—stomach cancer	0.000664	0.0104	CbGeAlD
Naloxone—Asthenia—Mitomycin—stomach cancer	0.000657	0.00726	CcSEcCtD
Naloxone—Diarrhoea—Mitomycin—stomach cancer	0.000627	0.00692	CcSEcCtD
Naloxone—CYP2C8—endocrine gland—stomach cancer	0.000606	0.00951	CbGeAlD
Naloxone—Hot flush—Docetaxel—stomach cancer	0.000598	0.0066	CcSEcCtD
Naloxone—Sweating—Irinotecan—stomach cancer	0.000598	0.0066	CcSEcCtD
Naloxone—ALB—lymph node—stomach cancer	0.000597	0.00936	CbGeAlD
Naloxone—Menopausal symptoms—Docetaxel—stomach cancer	0.000593	0.00655	CcSEcCtD
Naloxone—Vomiting—Mitomycin—stomach cancer	0.000582	0.00643	CcSEcCtD
Naloxone—Hot flush—Capecitabine—stomach cancer	0.000579	0.00639	CcSEcCtD
Naloxone—Menopausal symptoms—Capecitabine—stomach cancer	0.000574	0.00634	CcSEcCtD
Naloxone—CYP2C8—liver—stomach cancer	0.000547	0.00858	CbGeAlD
Naloxone—Nausea—Mitomycin—stomach cancer	0.000544	0.00601	CcSEcCtD
Naloxone—Ventricular tachycardia—Epirubicin—stomach cancer	0.00052	0.00574	CcSEcCtD
Naloxone—Flushing—Irinotecan—stomach cancer	0.000519	0.00574	CcSEcCtD
Naloxone—Cardiac disorder—Irinotecan—stomach cancer	0.000519	0.00574	CcSEcCtD
Naloxone—Irritability—Capecitabine—stomach cancer	0.000517	0.00571	CcSEcCtD
Naloxone—Injection site reaction—Epirubicin—stomach cancer	0.000517	0.00571	CcSEcCtD
Naloxone—Cardiac arrest—Capecitabine—stomach cancer	0.000515	0.00569	CcSEcCtD
Naloxone—ESR1—lymph node—stomach cancer	0.000509	0.00798	CbGeAlD
Naloxone—Angiopathy—Irinotecan—stomach cancer	0.000508	0.00561	CcSEcCtD
Naloxone—Coma—Methotrexate—stomach cancer	0.000507	0.00561	CcSEcCtD
Naloxone—ABCB1—hematopoietic system—stomach cancer	0.000506	0.00794	CbGeAlD
Naloxone—Mediastinal disorder—Irinotecan—stomach cancer	0.000504	0.00557	CcSEcCtD
Naloxone—Chills—Irinotecan—stomach cancer	0.000502	0.00555	CcSEcCtD
Naloxone—Nasopharyngitis—Docetaxel—stomach cancer	0.0005	0.00552	CcSEcCtD
Naloxone—CYP3A4—digestive system—stomach cancer	0.000497	0.0078	CbGeAlD
Naloxone—Pulmonary oedema—Methotrexate—stomach cancer	0.000494	0.00546	CcSEcCtD
Naloxone—Nasopharyngitis—Capecitabine—stomach cancer	0.000484	0.00535	CcSEcCtD
Naloxone—Ventricular tachycardia—Doxorubicin—stomach cancer	0.000481	0.00531	CcSEcCtD
Naloxone—Injection site reaction—Doxorubicin—stomach cancer	0.000478	0.00528	CcSEcCtD
Naloxone—Coma—Epirubicin—stomach cancer	0.000475	0.00525	CcSEcCtD
Naloxone—Pulmonary oedema—Epirubicin—stomach cancer	0.000463	0.00511	CcSEcCtD
Naloxone—ABCB1—epithelium—stomach cancer	0.000463	0.00725	CbGeAlD
Naloxone—Coma—Doxorubicin—stomach cancer	0.000439	0.00485	CcSEcCtD
Naloxone—Pulmonary oedema—Doxorubicin—stomach cancer	0.000428	0.00473	CcSEcCtD
Naloxone—Hypertension—Irinotecan—stomach cancer	0.000421	0.00465	CcSEcCtD
Naloxone—Depression—Capecitabine—stomach cancer	0.000416	0.0046	CcSEcCtD
Naloxone—ABCB1—pancreas—stomach cancer	0.000412	0.00646	CbGeAlD
Naloxone—CYP3A4—endocrine gland—stomach cancer	0.000411	0.00644	CbGeAlD
Naloxone—Convulsion—Fluorouracil—stomach cancer	0.000404	0.00447	CcSEcCtD
Naloxone—Hot flush—Epirubicin—stomach cancer	0.000403	0.00445	CcSEcCtD
Naloxone—Menopausal symptoms—Epirubicin—stomach cancer	0.0004	0.00442	CcSEcCtD
Naloxone—Nervous system disorder—Irinotecan—stomach cancer	0.00039	0.00431	CcSEcCtD
Naloxone—Irritability—Methotrexate—stomach cancer	0.000385	0.00425	CcSEcCtD
Naloxone—Hyperhidrosis—Irinotecan—stomach cancer	0.000384	0.00425	CcSEcCtD
Naloxone—Nervous system disorder—Fluorouracil—stomach cancer	0.000374	0.00413	CcSEcCtD
Naloxone—Hot flush—Doxorubicin—stomach cancer	0.000373	0.00412	CcSEcCtD
Naloxone—Tachycardia—Fluorouracil—stomach cancer	0.000372	0.00411	CcSEcCtD
Naloxone—CYP3A4—liver—stomach cancer	0.00037	0.00581	CbGeAlD
Naloxone—Menopausal symptoms—Doxorubicin—stomach cancer	0.00037	0.00409	CcSEcCtD
Naloxone—Cardiac disorder—Docetaxel—stomach cancer	0.000359	0.00397	CcSEcCtD
Naloxone—Flushing—Docetaxel—stomach cancer	0.000359	0.00397	CcSEcCtD
Naloxone—Cardiac arrest—Epirubicin—stomach cancer	0.000359	0.00396	CcSEcCtD
Naloxone—Paraesthesia—Irinotecan—stomach cancer	0.000357	0.00394	CcSEcCtD
Naloxone—ABCB1—lymphoid tissue—stomach cancer	0.000356	0.00559	CbGeAlD
Naloxone—Dyspnoea—Irinotecan—stomach cancer	0.000355	0.00392	CcSEcCtD
Naloxone—ABCB1—digestive system—stomach cancer	0.000352	0.00552	CbGeAlD
Naloxone—Angiopathy—Docetaxel—stomach cancer	0.000351	0.00388	CcSEcCtD
Naloxone—Mediastinal disorder—Docetaxel—stomach cancer	0.000349	0.00385	CcSEcCtD
Naloxone—Flushing—Capecitabine—stomach cancer	0.000348	0.00384	CcSEcCtD
Naloxone—Cardiac disorder—Capecitabine—stomach cancer	0.000348	0.00384	CcSEcCtD
Naloxone—Chills—Docetaxel—stomach cancer	0.000347	0.00384	CcSEcCtD
Naloxone—Gastrointestinal disorder—Irinotecan—stomach cancer	0.000343	0.00379	CcSEcCtD
Naloxone—Paraesthesia—Fluorouracil—stomach cancer	0.000342	0.00378	CcSEcCtD
Naloxone—Pain—Irinotecan—stomach cancer	0.00034	0.00376	CcSEcCtD
Naloxone—Angiopathy—Capecitabine—stomach cancer	0.00034	0.00375	CcSEcCtD
Naloxone—Dyspnoea—Fluorouracil—stomach cancer	0.00034	0.00375	CcSEcCtD
Naloxone—Mental disorder—Docetaxel—stomach cancer	0.000339	0.00374	CcSEcCtD
Naloxone—Mediastinal disorder—Capecitabine—stomach cancer	0.000338	0.00373	CcSEcCtD
Naloxone—Nasopharyngitis—Epirubicin—stomach cancer	0.000337	0.00373	CcSEcCtD
Naloxone—Chills—Capecitabine—stomach cancer	0.000336	0.00371	CcSEcCtD
Naloxone—Cardiac arrest—Doxorubicin—stomach cancer	0.000332	0.00367	CcSEcCtD
Naloxone—Gastrointestinal disorder—Fluorouracil—stomach cancer	0.000329	0.00363	CcSEcCtD
Naloxone—Mental disorder—Capecitabine—stomach cancer	0.000328	0.00363	CcSEcCtD
Naloxone—Pain—Fluorouracil—stomach cancer	0.000326	0.0036	CcSEcCtD
Naloxone—ABCB1—bone marrow—stomach cancer	0.000324	0.00509	CbGeAlD
Naloxone—Abdominal pain—Irinotecan—stomach cancer	0.000314	0.00347	CcSEcCtD
Naloxone—Body temperature increased—Irinotecan—stomach cancer	0.000314	0.00347	CcSEcCtD
Naloxone—Nasopharyngitis—Doxorubicin—stomach cancer	0.000312	0.00345	CcSEcCtD
Naloxone—Depression—Methotrexate—stomach cancer	0.00031	0.00342	CcSEcCtD
Naloxone—Tremor—Capecitabine—stomach cancer	0.000306	0.00338	CcSEcCtD
Naloxone—Body temperature increased—Fluorouracil—stomach cancer	0.000301	0.00333	CcSEcCtD
Naloxone—Sweating—Methotrexate—stomach cancer	0.000298	0.00329	CcSEcCtD
Naloxone—Convulsion—Docetaxel—stomach cancer	0.000292	0.00322	CcSEcCtD
Naloxone—Hypertension—Docetaxel—stomach cancer	0.000291	0.00321	CcSEcCtD
Naloxone—ABCB1—endocrine gland—stomach cancer	0.000291	0.00456	CbGeAlD
Naloxone—Asthenia—Irinotecan—stomach cancer	0.000285	0.00315	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—stomach cancer	0.000285	0.00315	CcSEcCtD
Naloxone—Hypertension—Capecitabine—stomach cancer	0.000282	0.00311	CcSEcCtD
Naloxone—Sweating—Epirubicin—stomach cancer	0.000279	0.00308	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—stomach cancer	0.000276	0.00305	CcSEcCtD
Naloxone—Diarrhoea—Irinotecan—stomach cancer	0.000272	0.00301	CcSEcCtD
Naloxone—Nervous system disorder—Docetaxel—stomach cancer	0.00027	0.00298	CcSEcCtD
Naloxone—Tachycardia—Docetaxel—stomach cancer	0.000268	0.00296	CcSEcCtD
Naloxone—Skin disorder—Docetaxel—stomach cancer	0.000267	0.00295	CcSEcCtD
Naloxone—ABCB1—liver—stomach cancer	0.000262	0.00411	CbGeAlD
Naloxone—Nervous system disorder—Capecitabine—stomach cancer	0.000261	0.00288	CcSEcCtD
Naloxone—Diarrhoea—Fluorouracil—stomach cancer	0.000261	0.00288	CcSEcCtD
Naloxone—Tachycardia—Capecitabine—stomach cancer	0.00026	0.00287	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—stomach cancer	0.000259	0.00286	CcSEcCtD
Naloxone—Skin disorder—Capecitabine—stomach cancer	0.000259	0.00286	CcSEcCtD
Naloxone—Sweating—Doxorubicin—stomach cancer	0.000258	0.00285	CcSEcCtD
Naloxone—Hyperhidrosis—Capecitabine—stomach cancer	0.000257	0.00284	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—stomach cancer	0.000253	0.0028	CcSEcCtD
Naloxone—Vomiting—Irinotecan—stomach cancer	0.000253	0.00279	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—stomach cancer	0.000251	0.00278	CcSEcCtD
Naloxone—Chills—Methotrexate—stomach cancer	0.00025	0.00276	CcSEcCtD
Naloxone—Paraesthesia—Docetaxel—stomach cancer	0.000247	0.00273	CcSEcCtD
Naloxone—Dyspnoea—Docetaxel—stomach cancer	0.000245	0.00271	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—stomach cancer	0.000244	0.0027	CcSEcCtD
Naloxone—Cardiac disorder—Epirubicin—stomach cancer	0.000242	0.00268	CcSEcCtD
Naloxone—Flushing—Epirubicin—stomach cancer	0.000242	0.00268	CcSEcCtD
Naloxone—Vomiting—Fluorouracil—stomach cancer	0.000242	0.00268	CcSEcCtD
Naloxone—Paraesthesia—Capecitabine—stomach cancer	0.000239	0.00264	CcSEcCtD
Naloxone—Gastrointestinal disorder—Docetaxel—stomach cancer	0.000237	0.00262	CcSEcCtD
Naloxone—Dyspnoea—Capecitabine—stomach cancer	0.000237	0.00262	CcSEcCtD
Naloxone—Angiopathy—Epirubicin—stomach cancer	0.000237	0.00262	CcSEcCtD
Naloxone—Nausea—Irinotecan—stomach cancer	0.000236	0.00261	CcSEcCtD
Naloxone—Mediastinal disorder—Epirubicin—stomach cancer	0.000235	0.0026	CcSEcCtD
Naloxone—Pain—Docetaxel—stomach cancer	0.000235	0.0026	CcSEcCtD
Naloxone—Chills—Epirubicin—stomach cancer	0.000234	0.00259	CcSEcCtD
Naloxone—Gastrointestinal disorder—Capecitabine—stomach cancer	0.00023	0.00254	CcSEcCtD
Naloxone—Mental disorder—Epirubicin—stomach cancer	0.000229	0.00253	CcSEcCtD
Naloxone—Pain—Capecitabine—stomach cancer	0.000228	0.00251	CcSEcCtD
Naloxone—Nausea—Fluorouracil—stomach cancer	0.000226	0.0025	CcSEcCtD
Naloxone—Cardiac disorder—Doxorubicin—stomach cancer	0.000224	0.00248	CcSEcCtD
Naloxone—Flushing—Doxorubicin—stomach cancer	0.000224	0.00248	CcSEcCtD
Naloxone—Tension—Epirubicin—stomach cancer	0.000223	0.00246	CcSEcCtD
Naloxone—Nervousness—Epirubicin—stomach cancer	0.000221	0.00244	CcSEcCtD
Naloxone—Angiopathy—Doxorubicin—stomach cancer	0.000219	0.00242	CcSEcCtD
Naloxone—Mediastinal disorder—Doxorubicin—stomach cancer	0.000218	0.0024	CcSEcCtD
Naloxone—Abdominal pain—Docetaxel—stomach cancer	0.000217	0.0024	CcSEcCtD
Naloxone—Body temperature increased—Docetaxel—stomach cancer	0.000217	0.0024	CcSEcCtD
Naloxone—Chills—Doxorubicin—stomach cancer	0.000217	0.00239	CcSEcCtD
Naloxone—Mental disorder—Doxorubicin—stomach cancer	0.000212	0.00234	CcSEcCtD
Naloxone—Abdominal pain—Capecitabine—stomach cancer	0.00021	0.00232	CcSEcCtD
Naloxone—Body temperature increased—Capecitabine—stomach cancer	0.00021	0.00232	CcSEcCtD
Naloxone—Convulsion—Methotrexate—stomach cancer	0.00021	0.00232	CcSEcCtD
Naloxone—Agitation—Epirubicin—stomach cancer	0.000209	0.00231	CcSEcCtD
Naloxone—Tension—Doxorubicin—stomach cancer	0.000206	0.00228	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	0.000205	0.00227	CcSEcCtD
Naloxone—Nervousness—Doxorubicin—stomach cancer	0.000204	0.00226	CcSEcCtD
Naloxone—ABCB1—lymph node—stomach cancer	0.000201	0.00315	CbGeAlD
Naloxone—Asthenia—Docetaxel—stomach cancer	0.000197	0.00218	CcSEcCtD
Naloxone—Convulsion—Epirubicin—stomach cancer	0.000197	0.00217	CcSEcCtD
Naloxone—Hypertension—Epirubicin—stomach cancer	0.000196	0.00217	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—stomach cancer	0.000194	0.00215	CcSEcCtD
Naloxone—Agitation—Doxorubicin—stomach cancer	0.000193	0.00213	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—stomach cancer	0.000192	0.00213	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	0.000192	0.00212	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—stomach cancer	0.000192	0.00212	CcSEcCtD
Naloxone—Asthenia—Capecitabine—stomach cancer	0.000191	0.00211	CcSEcCtD
Naloxone—Diarrhoea—Docetaxel—stomach cancer	0.000188	0.00208	CcSEcCtD
Naloxone—Convulsion—Doxorubicin—stomach cancer	0.000182	0.00201	CcSEcCtD
Naloxone—Diarrhoea—Capecitabine—stomach cancer	0.000182	0.00201	CcSEcCtD
Naloxone—Nervous system disorder—Epirubicin—stomach cancer	0.000182	0.00201	CcSEcCtD
Naloxone—Hypertension—Doxorubicin—stomach cancer	0.000181	0.002	CcSEcCtD
Naloxone—Tachycardia—Epirubicin—stomach cancer	0.000181	0.002	CcSEcCtD
Naloxone—Skin disorder—Epirubicin—stomach cancer	0.00018	0.00199	CcSEcCtD
Naloxone—Hyperhidrosis—Epirubicin—stomach cancer	0.000179	0.00198	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—stomach cancer	0.000178	0.00197	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	0.000178	0.00196	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—stomach cancer	0.000177	0.00195	CcSEcCtD
Naloxone—Vomiting—Docetaxel—stomach cancer	0.000175	0.00193	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—stomach cancer	0.000171	0.00189	CcSEcCtD
Naloxone—Pain—Methotrexate—stomach cancer	0.000169	0.00187	CcSEcCtD
Naloxone—Vomiting—Capecitabine—stomach cancer	0.000169	0.00187	CcSEcCtD
Naloxone—Nervous system disorder—Doxorubicin—stomach cancer	0.000168	0.00186	CcSEcCtD
Naloxone—Tachycardia—Doxorubicin—stomach cancer	0.000167	0.00185	CcSEcCtD
Naloxone—Skin disorder—Doxorubicin—stomach cancer	0.000167	0.00184	CcSEcCtD
Naloxone—Paraesthesia—Epirubicin—stomach cancer	0.000166	0.00184	CcSEcCtD
Naloxone—Hyperhidrosis—Doxorubicin—stomach cancer	0.000166	0.00183	CcSEcCtD
Naloxone—Dyspnoea—Epirubicin—stomach cancer	0.000165	0.00183	CcSEcCtD
Naloxone—Nausea—Docetaxel—stomach cancer	0.000163	0.0018	CcSEcCtD
Naloxone—Gastrointestinal disorder—Epirubicin—stomach cancer	0.00016	0.00177	CcSEcCtD
Naloxone—Pain—Epirubicin—stomach cancer	0.000159	0.00175	CcSEcCtD
Naloxone—Nausea—Capecitabine—stomach cancer	0.000158	0.00175	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—stomach cancer	0.000157	0.00173	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—stomach cancer	0.000157	0.00173	CcSEcCtD
Naloxone—Paraesthesia—Doxorubicin—stomach cancer	0.000154	0.0017	CcSEcCtD
Naloxone—Dyspnoea—Doxorubicin—stomach cancer	0.000153	0.00169	CcSEcCtD
Naloxone—Gastrointestinal disorder—Doxorubicin—stomach cancer	0.000148	0.00164	CcSEcCtD
Naloxone—Pain—Doxorubicin—stomach cancer	0.000147	0.00162	CcSEcCtD
Naloxone—Body temperature increased—Epirubicin—stomach cancer	0.000147	0.00162	CcSEcCtD
Naloxone—Abdominal pain—Epirubicin—stomach cancer	0.000147	0.00162	CcSEcCtD
Naloxone—Asthenia—Methotrexate—stomach cancer	0.000142	0.00157	CcSEcCtD
Naloxone—Abdominal pain—Doxorubicin—stomach cancer	0.000136	0.0015	CcSEcCtD
Naloxone—Body temperature increased—Doxorubicin—stomach cancer	0.000136	0.0015	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—stomach cancer	0.000136	0.0015	CcSEcCtD
Naloxone—Asthenia—Epirubicin—stomach cancer	0.000133	0.00147	CcSEcCtD
Naloxone—Diarrhoea—Epirubicin—stomach cancer	0.000127	0.0014	CcSEcCtD
Naloxone—Vomiting—Methotrexate—stomach cancer	0.000126	0.00139	CcSEcCtD
Naloxone—Asthenia—Doxorubicin—stomach cancer	0.000123	0.00136	CcSEcCtD
Naloxone—Vomiting—Epirubicin—stomach cancer	0.000118	0.0013	CcSEcCtD
Naloxone—Nausea—Methotrexate—stomach cancer	0.000118	0.0013	CcSEcCtD
Naloxone—Diarrhoea—Doxorubicin—stomach cancer	0.000117	0.0013	CcSEcCtD
Naloxone—Nausea—Epirubicin—stomach cancer	0.00011	0.00122	CcSEcCtD
Naloxone—Vomiting—Doxorubicin—stomach cancer	0.000109	0.0012	CcSEcCtD
Naloxone—Nausea—Doxorubicin—stomach cancer	0.000102	0.00113	CcSEcCtD
Naloxone—CREB1—Signaling Pathways—RHOA—stomach cancer	8.27e-06	3.43e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK3—stomach cancer	8.25e-06	3.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IRS2—stomach cancer	8.25e-06	3.42e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—RHOA—stomach cancer	8.24e-06	3.42e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CD44—stomach cancer	8.24e-06	3.42e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—MAPK1—stomach cancer	8.21e-06	3.41e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—EGFR—stomach cancer	8.21e-06	3.4e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CD44—stomach cancer	8.19e-06	3.4e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NOS3—stomach cancer	8.18e-06	3.39e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NOS3—stomach cancer	8.16e-06	3.38e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ENO1—stomach cancer	8.09e-06	3.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PDHA1—stomach cancer	8.07e-06	3.35e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ECHS1—stomach cancer	8.07e-06	3.35e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6R—stomach cancer	8e-06	3.32e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	8e-06	3.32e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CAV1—stomach cancer	8e-06	3.32e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—FGFR2—stomach cancer	7.98e-06	3.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOA1—stomach cancer	7.98e-06	3.31e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK3—stomach cancer	7.96e-06	3.3e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	7.95e-06	3.3e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—NOS3—stomach cancer	7.92e-06	3.29e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—MAPK1—stomach cancer	7.85e-06	3.26e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—EGFR—stomach cancer	7.85e-06	3.26e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—PIK3CA—stomach cancer	7.8e-06	3.23e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—PIK3CA—stomach cancer	7.77e-06	3.22e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—KRAS—stomach cancer	7.75e-06	3.22e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MYC—stomach cancer	7.75e-06	3.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—ERBB2—stomach cancer	7.65e-06	3.18e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—ERBB2—stomach cancer	7.63e-06	3.17e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PRKCB—stomach cancer	7.61e-06	3.16e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMP—stomach cancer	7.59e-06	3.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—FADS1—stomach cancer	7.59e-06	3.15e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6ST—stomach cancer	7.58e-06	3.14e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—MAPK1—stomach cancer	7.58e-06	3.14e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—EGFR—stomach cancer	7.58e-06	3.14e-05	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	7.57e-06	3.14e-05	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—PIK3CA—stomach cancer	7.5e-06	3.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SERPINE1—stomach cancer	7.49e-06	3.11e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—KRAS—stomach cancer	7.42e-06	3.08e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IRS2—stomach cancer	7.31e-06	3.03e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APC—stomach cancer	7.28e-06	3.02e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—stomach cancer	7.26e-06	3.01e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PTGS2—stomach cancer	7.25e-06	3.01e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—stomach cancer	7.24e-06	3e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—RHOA—stomach cancer	7.23e-06	3e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—HRAS—stomach cancer	7.21e-06	2.99e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—HRAS—stomach cancer	7.19e-06	2.98e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CD44—stomach cancer	7.18e-06	2.98e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—KRAS—stomach cancer	7.16e-06	2.97e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NOS3—stomach cancer	7.15e-06	2.97e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—PIK3CA—stomach cancer	7.12e-06	2.95e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—SREBF2—stomach cancer	7.11e-06	2.95e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1B—stomach cancer	7.09e-06	2.94e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CAV1—stomach cancer	7.09e-06	2.94e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOA1—stomach cancer	7.07e-06	2.93e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1B—stomach cancer	7.07e-06	2.93e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—RORA—stomach cancer	7.02e-06	2.91e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPP2R1A—stomach cancer	7.01e-06	2.91e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK3—stomach cancer	6.97e-06	2.89e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPP2R1A—stomach cancer	6.97e-06	2.89e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—stomach cancer	6.9e-06	2.86e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—stomach cancer	6.88e-06	2.85e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—stomach cancer	6.88e-06	2.85e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTP1—stomach cancer	6.87e-06	2.85e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTP1—stomach cancer	6.83e-06	2.84e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—PIK3CA—stomach cancer	6.81e-06	2.83e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—HMOX1—stomach cancer	6.78e-06	2.81e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCND1—stomach cancer	6.76e-06	2.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6R—stomach cancer	6.76e-06	2.81e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—JUN—stomach cancer	6.75e-06	2.8e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PRKCB—stomach cancer	6.75e-06	2.8e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCND1—stomach cancer	6.74e-06	2.8e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—HMOX1—stomach cancer	6.74e-06	2.8e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—JUN—stomach cancer	6.73e-06	2.79e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6ST—stomach cancer	6.72e-06	2.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—ERBB2—stomach cancer	6.69e-06	2.78e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—MAPK1—stomach cancer	6.64e-06	2.75e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—EGFR—stomach cancer	6.63e-06	2.75e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—HRAS—stomach cancer	6.59e-06	2.73e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALDOB—stomach cancer	6.58e-06	2.73e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—PIK3CA—stomach cancer	6.58e-06	2.73e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MMP9—stomach cancer	6.57e-06	2.72e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MMP9—stomach cancer	6.54e-06	2.72e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CDKN1A—stomach cancer	6.54e-06	2.71e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CDKN1A—stomach cancer	6.52e-06	2.71e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK3—stomach cancer	6.51e-06	2.7e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APC—stomach cancer	6.46e-06	2.68e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—TYMS—stomach cancer	6.39e-06	2.65e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK8—stomach cancer	6.39e-06	2.65e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK8—stomach cancer	6.37e-06	2.64e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—TYMS—stomach cancer	6.35e-06	2.64e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—stomach cancer	6.34e-06	2.63e-05	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—PIK3CA—stomach cancer	6.34e-06	2.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SERPINE1—stomach cancer	6.33e-06	2.63e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—GSTM1—stomach cancer	6.32e-06	2.62e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—stomach cancer	6.31e-06	2.62e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—HRAS—stomach cancer	6.3e-06	2.62e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—GSTM1—stomach cancer	6.28e-06	2.61e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—KRAS—stomach cancer	6.27e-06	2.6e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1B—stomach cancer	6.2e-06	2.57e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—MAPK1—stomach cancer	6.19e-06	2.57e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALOX5—stomach cancer	6.12e-06	2.54e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—RHOA—stomach cancer	6.11e-06	2.53e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPP2R1A—stomach cancer	6.1e-06	2.53e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—HRAS—stomach cancer	6.08e-06	2.52e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NOS3—stomach cancer	6.05e-06	2.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—stomach cancer	6.03e-06	2.5e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—DPYD—stomach cancer	6.02e-06	2.5e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6R—stomach cancer	6e-06	2.49e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTP1—stomach cancer	5.99e-06	2.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ERCC2—stomach cancer	5.94e-06	2.46e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCND1—stomach cancer	5.91e-06	2.45e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—HMOX1—stomach cancer	5.91e-06	2.45e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—ERCC2—stomach cancer	5.9e-06	2.45e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—stomach cancer	5.9e-06	2.45e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—stomach cancer	5.9e-06	2.45e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—stomach cancer	5.88e-06	2.44e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—KRAS—stomach cancer	5.85e-06	2.43e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—stomach cancer	5.84e-06	2.42e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—stomach cancer	5.82e-06	2.42e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—stomach cancer	5.82e-06	2.41e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—PIK3CA—stomach cancer	5.76e-06	2.39e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MMP9—stomach cancer	5.74e-06	2.38e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CDKN1A—stomach cancer	5.72e-06	2.37e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—ERBB2—stomach cancer	5.65e-06	2.35e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MAPK3—stomach cancer	5.62e-06	2.33e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SERPINE1—stomach cancer	5.61e-06	2.33e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—MTHFR—stomach cancer	5.58e-06	2.32e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK8—stomach cancer	5.58e-06	2.32e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK3—stomach cancer	5.58e-06	2.31e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—TYMS—stomach cancer	5.57e-06	2.31e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK3—stomach cancer	5.56e-06	2.31e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—MTHFR—stomach cancer	5.55e-06	2.3e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—GSTM1—stomach cancer	5.5e-06	2.28e-05	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—MYC—stomach cancer	5.46e-06	2.27e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MYC—stomach cancer	5.42e-06	2.25e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—RHOA—stomach cancer	5.42e-06	2.25e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MYC—stomach cancer	5.41e-06	2.24e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—PIK3CA—stomach cancer	5.37e-06	2.23e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—stomach cancer	5.36e-06	2.22e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NOS3—stomach cancer	5.36e-06	2.22e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—HRAS—stomach cancer	5.33e-06	2.21e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTT1—stomach cancer	5.32e-06	2.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—MAPK1—stomach cancer	5.31e-06	2.2e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—EGFR—stomach cancer	5.31e-06	2.2e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—MAPK1—stomach cancer	5.29e-06	2.19e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—EGFR—stomach cancer	5.29e-06	2.19e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2A6—stomach cancer	5.26e-06	2.18e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1B—stomach cancer	5.24e-06	2.17e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—stomach cancer	5.2e-06	2.16e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ERCC2—stomach cancer	5.17e-06	2.15e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—stomach cancer	5.15e-06	2.14e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAV1—stomach cancer	5.15e-06	2.14e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOA1—stomach cancer	5.14e-06	2.13e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAV1—stomach cancer	5.12e-06	2.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—AKR1C3—stomach cancer	5.12e-06	2.12e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOA1—stomach cancer	5.11e-06	2.12e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—stomach cancer	5.1e-06	2.12e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—stomach cancer	5.1e-06	2.12e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—ERBB2—stomach cancer	5.01e-06	2.08e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—KRAS—stomach cancer	5.01e-06	2.08e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—KRAS—stomach cancer	5e-06	2.07e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCND1—stomach cancer	5e-06	2.07e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ENO1—stomach cancer	4.99e-06	2.07e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—stomach cancer	4.99e-06	2.07e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—HRAS—stomach cancer	4.97e-06	2.06e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.92e-06	2.04e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.89e-06	2.03e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK3—stomach cancer	4.87e-06	2.02e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—MTHFR—stomach cancer	4.86e-06	2.02e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MMP9—stomach cancer	4.85e-06	2.01e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CDKN1A—stomach cancer	4.83e-06	2e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—stomach cancer	4.75e-06	1.97e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MYC—stomach cancer	4.74e-06	1.97e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK8—stomach cancer	4.72e-06	1.96e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1B—stomach cancer	4.64e-06	1.93e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—MAPK1—stomach cancer	4.64e-06	1.92e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—EGFR—stomach cancer	4.64e-06	1.92e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—PIK3CA—stomach cancer	4.6e-06	1.91e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—PIK3CA—stomach cancer	4.59e-06	1.9e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—stomach cancer	4.53e-06	1.88e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—stomach cancer	4.5e-06	1.87e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAV1—stomach cancer	4.49e-06	1.86e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOA1—stomach cancer	4.48e-06	1.86e-05	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PIK3CA—stomach cancer	4.46e-06	1.85e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—stomach cancer	4.45e-06	1.85e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—stomach cancer	4.44e-06	1.84e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCND1—stomach cancer	4.43e-06	1.84e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CD44—stomach cancer	4.42e-06	1.83e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—stomach cancer	4.42e-06	1.83e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—KRAS—stomach cancer	4.38e-06	1.82e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—stomach cancer	4.36e-06	1.81e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—stomach cancer	4.31e-06	1.79e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MMP9—stomach cancer	4.3e-06	1.78e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CDKN1A—stomach cancer	4.29e-06	1.78e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—HRAS—stomach cancer	4.26e-06	1.77e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—HRAS—stomach cancer	4.25e-06	1.76e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK8—stomach cancer	4.18e-06	1.74e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK3—stomach cancer	4.12e-06	1.71e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—stomach cancer	4.08e-06	1.69e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—ALB—stomach cancer	4.07e-06	1.69e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—stomach cancer	4.06e-06	1.69e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—PIK3CA—stomach cancer	4.02e-06	1.67e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MYC—stomach cancer	4.01e-06	1.66e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—stomach cancer	3.94e-06	1.64e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—MAPK1—stomach cancer	3.92e-06	1.63e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—EGFR—stomach cancer	3.92e-06	1.63e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—stomach cancer	3.89e-06	1.62e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NOS3—stomach cancer	3.89e-06	1.62e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—NOS3—stomach cancer	3.87e-06	1.61e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—stomach cancer	3.86e-06	1.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—stomach cancer	3.82e-06	1.59e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.76e-06	1.56e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—HRAS—stomach cancer	3.72e-06	1.54e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—KRAS—stomach cancer	3.7e-06	1.54e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTP1—stomach cancer	3.69e-06	1.53e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK3—stomach cancer	3.65e-06	1.52e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—HMOX1—stomach cancer	3.64e-06	1.51e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—stomach cancer	3.56e-06	1.48e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PTGS2—stomach cancer	3.56e-06	1.48e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MYC—stomach cancer	3.55e-06	1.47e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—ALB—stomach cancer	3.55e-06	1.47e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PTGS2—stomach cancer	3.54e-06	1.47e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—MAPK1—stomach cancer	3.48e-06	1.44e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—EGFR—stomach cancer	3.48e-06	1.44e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—TYMS—stomach cancer	3.43e-06	1.42e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—PIK3CA—stomach cancer	3.4e-06	1.41e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NOS3—stomach cancer	3.39e-06	1.41e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—GSTM1—stomach cancer	3.39e-06	1.41e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—stomach cancer	3.29e-06	1.37e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—KRAS—stomach cancer	3.28e-06	1.36e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ERCC2—stomach cancer	3.19e-06	1.32e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—HRAS—stomach cancer	3.15e-06	1.31e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PTGS2—stomach cancer	3.1e-06	1.29e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—PIK3CA—stomach cancer	3.02e-06	1.25e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—stomach cancer	3.01e-06	1.25e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—MTHFR—stomach cancer	3e-06	1.24e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—stomach cancer	2.92e-06	1.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—HRAS—stomach cancer	2.79e-06	1.16e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAV1—stomach cancer	2.76e-06	1.15e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOA1—stomach cancer	2.76e-06	1.14e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—stomach cancer	2.67e-06	1.11e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—stomach cancer	2.43e-06	1.01e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PIK3CA—stomach cancer	2.19e-06	9.09e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—ALB—stomach cancer	2.18e-06	9.06e-06	CbGpPWpGaD
Naloxone—ALB—Metabolism—PIK3CA—stomach cancer	2.18e-06	9.04e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NOS3—stomach cancer	2.09e-06	8.67e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PTGS2—stomach cancer	1.91e-06	7.93e-06	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PIK3CA—stomach cancer	1.91e-06	7.92e-06	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.18e-06	4.88e-06	CbGpPWpGaD
